ENDOPROSTHESIS CONTAINING MAGNETIC INDUCTION PARTICLES

• US 20080071353A1
• Filed: 09/14/2007
• Published: 03/20/2008
• Est. Priority Date: 09/15/2006
• Status: Abandoned Application

• Current Assignee: Boston Scientific Scimed, Inc. (Boston Scientific Corporation)
• Original Assignee: Boston Scientific Scimed, Inc. (Boston Scientific Corporation)
• Inventors: Weber, Jan, Atanasoska, Liliana
• Application Number:
  US11/855,693
• Publication Number:
  US 20080071353A1
• Time in Patent Office: Days
• US Class Current: 623/1.15
• CPC Class Codes: A61L 2400/12 Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
• CPC Class Codes: A61L 31/148 Materials at least partially resorbable by the body
• CPC Class Codes: A61L 31/18 Materials at least partially X-ray or laser opaque

Abstract

Endoprostheses (e.g., stents) containing one or more magnetic induction particles (e.g., nanoparticles) are disclosed.

Claims

1. A stent comprising a bioerodible portion and a plurality of magnetic induction particles, said particles having a metal coating.

2. The stent of claim 1, wherein the magnetic particles contain a metal selected from iron, nickel and cobalt.

3. The stent of claim 1, wherein the magnetic particles are coated with a radiopaque material.

4. The stent of claim 1, wherein the particles are coated with gold, platinum or silver.

5. The stent of claim 1, wherein the magnetic particles are selected from the group consisting of Co@Au, Co@Ag, Fe3O4@Au, Fe3O4®

Ag, FePt and CoFe@Au.

6. The stent of claim 1, wherein the magnetic particles are ferromagnetic, paramagnetic or super-paramagnetic.

7. The stent of claim 1, wherein the magnetic particles have a diameter from about 10 to 1000 nm.

8. The stent of claim 1, wherein the particles have a diameter from about 3 to 50 nm.

9. The stent of claim 1, wherein the particles have a volume from about 10 to 500 cubic nm.

10. The stent of claim 1, wherein the particles include a polymer coating.

11. The stent of claim 1, wherein the magnetic particles are coupled to a functional group selected from the group consisting of an alkyl, di- or tri-fluoromethyl, hydroxyl, ether, carboxylic acid, ester, amide, halogen (e.g., chloro, bromo), nitrile, amine, borate, alkene, alkyne, diacetylene, aryl, oligo(phenylene ethylene), quinone, oligo(ethylene glycol), sulfone, epoxide, pyrene, azobenzene, silyl, carbonyl, imide, anhydride, thiol, ammonium, isocyanate and urethane.

12. The stent of claim 1, wherein the particles include a polyelectrolyte coating.

13. The stent of claim 1, wherein the particles are bonded to the erodible portion.

14. The stent of claim 1, wherein the particles are in a separate layer from the erodible portion.

15. The stent of claim 1, wherein the magnetic particles are embedded in the biocrodible portion.

16. The stent of claim 1, wherein the magnetic particles are located within a polyelectrolyte coating.

17. The stent of claim 1, wherein the magnetic particles are located within a conducting polymer.

18. The stent of claim 1, wherein the magnetic particles are located within an amphiphylic block copolymer.

19. The stent of claim 1, wherein the magnetic particles are located within a inorganic coating.

20. The stent of claim 1, wherein the particles are embedded in a common layer with a drug.

21. The stent of claim 20, wherein the common layer is a polymer.

22. The stent of claim 21, wherein the common layer is bioerodible.

23. The stent of claim 21, wherein the common layer is non-bioerodible.

24. The stent of claim 1, wherein the particles are attached to a surface of the stent.

25. The stent of claim 1, particles are covalently bound to the stent.

26. The stent of claim 1, wherein the bioerodible portion comprises a bioerodible metal, a bioerodible metal alloy, a bioerodible polymer, or a mixture thereof.

27. The stent of claim 26, wherein the bioerodible metal is magnesium or iron.

28. The stent of claim 1, further comprising at least one therapeutic agent.

29. The stent of claim 22, wherein at least one therapeutic agent is embedded in the bioerodible portion.

30. The stent of claim 28, wherein at least one therapeutic agent is contained in a capsule.

41. A method comprising implanting the stent of claim 1 in a body passageway of an organism and applying a magnetic field to control erosion rate of the erodible portion.

42. The method of claim 41, comprising applying a magnetic field to control the permeability of the stent to body fluid.

31. A stent comprising a substantially tubular polymer body and magnetic induction particles having a size of about 1 to 1000 nm.

32. The stent of claim 31 wherein the particles have a size of about 10 to 100 nm.

33. The stent of claim 31 wherein the particles are coated with a metal.

34. The stent of claim 31 wherein particles contain iron, nickel or cobalt and are coated with silver, gold or platinum.

35. The stent of claim 31 wherein the polymer body is bioerodible.

36. A drug delivering stent comprising a tubular body and including magnetic induction particles having a size of about 1 to 1000 nm.

37. The stent of claim 36, wherein the drug is in a coating on the stent.

38. The stent of claim 36, wherein the coating is bioerodible.

39. The stent of claim 36, wherein the coating is non-bioerodible.

40. The stent of claim 36, wherein the particles are in the coating.

43. The method of c]aim 41, comprising visualizing the stent by MRI or X-ray fluoroscopy.

44. A method of making a stent comprising:

providing a plurality of metal particles, said particles having a size of about 1 to 500 nm, and a functionalized organic surface

forming a dispersion of magnetic particles in a polymer, and

utilizing said dispersion to form a stent.

45. The method of claim 44 comprising forming said dispersion by combining said particles and polymer in an organic solvent.

46. The method of claims 44 or 45 comprising incorporating a drug into said polymer.

47. The method of claim 46 comprising combining said drug with said particles in said dispersion.

48. The method of claim 44 comprising applying said dispersion to a stent body.